Compounder Stocks to Buy in November 2026: 5 Names on the Watchlist

The compounder stocks to buy in November 2026 start with five listed names: Ajanta Pharma, Menon Bearings, Dr Lal PathLabs, Elgi Equipments and KFin Technologies. Compounder stocks are companies that grow profit every year while earning high returns on equity with little debt, so earnings build on themselves over time.

This article ranks none of them as a sure thing. It lays out the numbers each company has reported, how the shares are priced today and what an investor should check before adding any of these compounder stocks to buy to a portfolio. All prices are NSE closing prices of 3 November 2026, and financials come from company filings.

Click Here – Get Free Investment Predictions

Which Are the Best Compounder Stocks to Buy in November 2026?

The best compounder stocks to buy in November 2026 for a watchlist are Ajanta Pharma, Menon Bearings, Dr Lal PathLabs, Elgi Equipments and KFin Technologies. They were picked because each has complete reported financials, profit in the latest quarter and an NSE listing. The table puts their market data side by side.

Company	CMP (Rs)	Market Cap	P/E	ROE	Dividend Yield
Ajanta Pharma	3,320	Rs 43,234 crore	38.10	23.33%	0.81%
Menon Bearings	321.50	Rs 1,506 crore	34.27	20.64%	0.74%
Dr Lal PathLabs	1,926	Rs 32,115 crore	58.78	20.13%	1.07%
Elgi Equipments	532.40	Rs 16,281 crore	36.36	19.28%	0.53%
KFin Technologies	861.60	Rs 14,910 crore	42.76	21.47%	1.39%

On valuation, Elgi Equipments trades below the industry P/E; Ajanta Pharma, Menon Bearings, Dr Lal PathLabs and KFin Technologies sit close to it. Valuation is the first filter for any compounder stocks to buy list, and it is covered again in the risk section.

Why These Compounder Stocks to Buy Are in Focus

In this list, net profit rose in each of the last three financial years, from FY24 to FY26, and return on equity ranges from about 19% to 23%. Debt to equity is 0.25 or lower for every company. The list covers a branded pharma company, an auto components maker, a diagnostics chain, an air compressor maker and a registrar and technology services company. Investors comparing the best compounder stocks in India usually check how long the growth record is and whether returns stay high as the business grows.

Ajanta Pharma: The Branded Generics Specialist Among Compounder Stocks to Buy

Ajanta Pharma is a branded generics company with a strong presence in dermatology, ophthalmology and cardiology in India, Africa and Asia. Its market capitalisation is Rs 43,234 crore, the share price is Rs 3,320 and the P/E of 38.10 compares with an industry P/E of 37.65.

Over FY26, net profit rose 14.7% to Rs 1,056 crore on revenue of Rs 5,625 crore, which was up 18.6%. The latest quarter, the June 2026 quarter, brought revenue of Rs 1,697 crore, up 27.7% year on year, and net profit of Rs 334 crore, up 30.9%.

Return on equity is 23.33%, debt-to-equity is 0.06, and the dividend yield is 0.81%. Promoters hold 63.47%, foreign institutions 7.63% and domestic institutions 21.94% as of September 2026. Domestic institutional holding has risen from 17.90% to 21.94% over the last year.

Menon Bearings: A Small-Cap Engine Bearing Maker Among Compounder Stocks to Buy

Menon Bearings is a maker of engine bearings, bushes and aluminium die castings, mainly for automakers. The stock trades at Rs 321.50 with a market capitalisation of Rs 1,506 crore and a P/E of 34.27, against an industry P/E of 36.13.

FY26 revenue rose 23.2% to Rs 300 crore and net profit rose 53.4% to Rs 38.2 crore. In the June 2026 quarter, revenue grew 37.0% year on year to Rs 94.3 crore, while net profit grew 67.4% to Rs 14.1 crore.

Return on equity is 20.64%, debt-to-equity is 0.25, and the dividend yield is 0.74%. Promoters hold 66.66%, foreign institutions 0.21% and domestic institutions 2.16% as of September 2026. Domestic institutional holding has risen from 0.00% to 2.16% over the last year.

Check Compounder Stocks Live on the Univest Screener

Dr Lal PathLabs: The Diagnostics Leader Among Compounder Stocks to Buy

Dr Lal PathLabs is one of India's largest diagnostic chains, with a national network of labs and collection centres. At Rs 1,926, the stock has a market capitalisation of Rs 32,115 crore and trades at 58.78 times earnings, while the industry P/E is 61.50.

Reported numbers show FY26 revenue of Rs 2,864 crore, up 12.1% year on year, with net profit at Rs 510 crore, up 3.6%. The June 2026 quarter added revenue of Rs 830 crore (up 18.9%) and net profit of Rs 170 crore (up 27.2%).

Return on equity is 20.13%, debt-to-equity is 0.08, and the dividend yield is 1.07%. Promoters hold 52.93%, foreign institutions 18.73% and domestic institutions 21.58% as of September 2026. Domestic institutional holding has risen from 18.49% to 21.58% over the last year.

Elgi Equipments: The Air Compressor Specialist Among Compounder Stocks to Buy

Elgi Equipments is an air compressor maker with a large international business. Its market capitalisation is Rs 16,281 crore, the share price is Rs 532.40 and the P/E of 36.36 compares with an industry P/E of 42.61.

Over FY26, net profit rose 22.8% to Rs 430 crore on revenue of Rs 4,068 crore, which was up 14.0%. The latest quarter, the June 2026 quarter, brought revenue of Rs 1,083 crore, up 22.1% year on year, and net profit of Rs 103 crore, up 20.7%.

Return on equity is 19.28%, debt-to-equity is 0.24, and the dividend yield is 0.53%. Promoters hold 31.19%, foreign institutions 20.20% and domestic institutions 11.47% as of September 2026. Domestic institutional holding has risen from 6.25% to 11.47% over the last year.

KFin Technologies: The Registrar and Technology Name Among Compounder Stocks to Buy

KFin Technologies is a registrar and technology services company for mutual funds and issuers. The stock trades at Rs 861.60 with a market capitalisation of Rs 14,910 crore and a P/E of 42.76, against an industry P/E of 42.66.

FY26 revenue rose 19.1% to Rs 1,344 crore and net profit rose 3.3% to Rs 344 crore. In the September 2026 quarter, revenue grew 28.1% year on year to Rs 410 crore, while net profit grew 7.5% to Rs 100 crore.

Return on equity is 21.47%, and the dividend yield is 1.39%. Promoters hold 14.06%, foreign institutions 20.07% and domestic institutions 37.55% as of September 2026. Domestic institutional holding has risen from 24.80% to 37.55% over the last year.

Download the Univest iOS App or Univest Android App to track these compounder stocks live and get daily stock recommendations.

Growth Snapshot: Latest Full Year and Latest Quarter

The table compares year-on-year growth in revenue and net profit for all five compounder stocks, using filed results.

Company	Full-Year Revenue Growth	Full-Year Profit Growth	Latest Quarter	Quarter Revenue Growth	Quarter Profit Growth
Ajanta Pharma	18.6%	14.7%	Jun 2026	27.7%	30.9%
Menon Bearings	23.2%	53.4%	Jun 2026	37.0%	67.4%
Dr Lal PathLabs	12.1%	3.6%	Jun 2026	18.9%	27.2%
Elgi Equipments	14.0%	22.8%	Jun 2026	22.1%	20.7%
KFin Technologies	19.1%	3.3%	Sep 2026	28.1%	7.5%

Factors That Move Compounder Stocks to Buy

Four factors tend to drive compounder stocks, and each one is worth checking before a purchase.

• Profit record: Rising profit every year is the base of compounding.
• Return on equity: High returns let the business grow without much debt.
• Low debt: Light borrowings protect the growth path.
• Valuation: Reliable growers often trade at premium multiples.

Risks to Keep in Mind Before Buying Compounder Stocks

The first risk is valuation, since a long growth record is usually reflected in the share price. The second is that three years is a short window, so older records and the next few quarters also matter. Review results every quarter.

On the numbers, Dr Lal PathLabs trades at the highest P/E on this list at 58.78, so its earnings need to keep growing to support the price. Compounder stocks to buy can still fall when markets turn weak, and a staggered entry has historically suited investors better than a lump-sum purchase.

How to Choose Compounder Stocks to Buy

• Check the record: Look beyond three years if you can.
• Review ROE: Returns should hold as the business grows.
• Study cash flow: Profit should be backed by cash.
• Compare valuations: Look at P/E against growth.

How to Invest in Compounder Stocks

1. Shortlist two or three companies from this list that match your risk appetite.
2. Open the Univest Screener and compare P/E, ROE and debt for each stock.
3. Check the latest quarterly results and shareholding pattern on NSE or BSE.
4. Decide an amount you can hold for three to five years and split it into two or three purchases.
5. Review the holding after every quarterly result instead of reacting to daily price moves.

Conclusion

Menon Bearings offers the lowest P/E on this list at 34.27, Ajanta Pharma has the highest return on equity at 23.33%, and Menon Bearings posted the fastest net profit growth in its latest full year at 53.4%. Among the best compounder stocks in India, these five give investors a spread of size, valuation and growth, so the right pick depends on risk appetite and holding period. Spread the entry, keep position sizes sensible and consult a SEBI-registered advisor before investing in any of these compounder stocks to buy.

Frequently Asked Questions on Compounder Stocks to Buy

Which are the best compounder stocks to buy in November 2026?

Ans. The five compounder stocks on the November 2026 watchlist are Ajanta Pharma, Menon Bearings, Dr Lal PathLabs, Elgi Equipments and KFin Technologies. Menon Bearings has the lowest P/E at 34.27, Ajanta Pharma has the highest ROE at 23.33%, and Menon Bearings grew net profit 53.4% in its latest full year. This is educational content, not investment advice, so please consult a SEBI-registered advisor.

Is Ajanta Pharma a good stock to buy from this Compounder list?

Ans. Ajanta Pharma is the largest company on this list with a market capitalisation of Rs 43,234 crore and a P/E of 38.10 against an industry P/E of 37.65. Its FY26 revenue rose 18.6% and net profit rose 14.7%, with return on equity at 23.33%. Whether it suits you depends on your risk appetite and holding period, so please consult a SEBI-registered advisor before investing.

Are these compounder stocks expensive right now?

Ans. Valuations vary across the group. Ajanta Pharma trades at a P/E of 38.10, Menon Bearings trades at a P/E of 34.27, Dr Lal PathLabs trades at a P/E of 58.78, Elgi Equipments trades at a P/E of 36.36, KFin Technologies trades at a P/E of 42.76, against industry multiples ranging from 36.13 to 61.50. Higher multiples reflect faster growth but also leave less room for earnings misses, so entry price deserves attention.

Which of these compounder stocks pay a dividend?

Ans. Dividend yields on this list are Ajanta Pharma 0.81%, Menon Bearings 0.74%, Dr Lal PathLabs 1.07%, Elgi Equipments 0.53%, KFin Technologies 1.39%. Yields are modest across the group, so most investors look at these stocks for growth in earnings rather than for income, and payouts can change with company profits.

Which stock on this list has the highest return on equity?

Ans. Ajanta Pharma has the highest ROE on this list at 23.33%, followed by KFin Technologies at 21.47% and Menon Bearings at 20.64%. A higher ROE shows a company earns more profit on shareholder capital, but it should be read alongside valuation and debt.

What are the risks of investing in compounder stocks?

Ans. The main risks are premium valuations, a short three-year window and a possible slowdown in growth. On this list, Dr Lal PathLabs trades at the highest P/E of 58.78, which leaves less room for earnings disappointments. Staggered buying and a long holding period can help manage these risks.

How can I invest in compounder stocks in India?

Ans. You can buy these stocks directly on NSE or BSE through a demat account, and compare them first on the Univest Screener using P/E, ROE and debt. Many investors split the amount across two or three purchases and review the holding after each quarterly result. Sector-themed mutual funds and ETFs are another route for investors who prefer diversification.